Key Highlights
- Citius Pharmaceuticals shares closed up 25% at $0.78.
- Majority-owned Citius Oncology reported accelerating LYMPHIR uptake in CTCL.
- New institutional accounts rose 78% quarter-over-quarter, with 42 institutions reached.
- Vial orders increased 31%, supported by broad payer coverage and early wholesaler reorders.
Citius Pharmaceuticals (NASDAQ: CTXR) shares closed up 25% at $0.78 after majority-owned Citius Oncology reported accelerating LYMPHIR uptake in cutaneous T-cell lymphoma (CTCL).
What Happened
New institutional accounts rose 78% quarter-over-quarter, with the company reaching 42 institutions, while vial orders increased 31%.
The growth was supported by broad payer coverage and early wholesaler reorders.
Market Reaction
Shares rose sharply as investors responded to the combination of accelerating institutional adoption, rising vial orders, and supportive payer dynamics for LYMPHIR's commercial launch.
Outlook
Continued growth in institutional accounts and vial orders, alongside sustained payer coverage, is likely to remain the key factor shaping sentiment toward Citius Pharmaceuticals' stock going forward.
Why did Citius Pharmaceuticals shares rise 25%?
Shares rose after majority-owned Citius Oncology reported accelerating LYMPHIR uptake, with new institutional accounts up 78% quarter-over-quarter and vial orders up 31%.
How many institutions has LYMPHIR reached?
42 institutions.
What is supporting LYMPHIR's commercial growth?
Broad payer coverage and early wholesaler reorders.






Please wait processing your request...